INT88077

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 2000
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 5
Disease Relevance 5.22
Pain Relevance 3.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Tnfrsf11b) extracellular region (Tnfrsf11b) proteinaceous extracellular matrix (Tnfrsf11b)
extracellular matrix organization (Tnfrsf11b)
Anatomy Link Frequency
osteoclast 3
fibroblasts 2
Tnfrsf11b (Mus musculus)
Pain Link Frequency Relevance Heat
Cancer pain 16 99.00 Very High Very High Very High
Pain 16 98.80 Very High Very High Very High
Dorsal horn 1 97.08 Very High Very High Very High
Spinal cord 7 96.60 Very High Very High Very High
Inflammation 20 95.52 Very High Very High Very High
cytokine 56 94.48 High High
IPN 1 92.76 High High
rheumatoid arthritis 2 85.44 High High
Analgesic 1 66.64 Quite High
chemokine 12 22.48 Low Low
Disease Link Frequency Relevance Heat
Bone Cancer 20 98.90 Very High Very High Very High
Pain 13 98.80 Very High Very High Very High
Apoptosis 1 96.48 Very High Very High Very High
INFLAMMATION 20 95.52 Very High Very High Very High
Cancer 13 93.20 High High
Inflammatory Pain 1 92.76 High High
Neuropathic Pain 1 91.92 High High
Disease 6 86.80 High High
Rheumatoid Arthritis 2 85.44 High High
Wound Healing 64 81.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibits osteoclast activity, also blocks behaviors indicative of pain in mice with bone cancer.
Localization (secreted) of osteoprotegerin in osteoclast associated with pain and bone cancer
1) Confidence 0.80 Published 2000 Journal Nat. Med. Section Abstract Doc Link 10802707 Disease Relevance 1.01 Pain Relevance 0.74
Administration of osteoprotegerin, a naturally secreted decoy receptor that inhibits osteoclast maturation and activity and induces osteoclast apoptosis, or vehicle was begun at 12 days, when significant bone destruction had already occurred, and administration was continued daily until day 21.
Localization (secreted) of osteoprotegerin in osteoclast associated with apoptosis
2) Confidence 0.71 Published 2001 Journal Cancer Res. Section Abstract Doc Link 11358823 Disease Relevance 1.50 Pain Relevance 0.80
To determine whether this mouse model of bone cancer could be used to define the basic mechanisms giving rise to bone cancer pain, we targeted excessive osteoclast activity using osteoprotegerin, a secreted decoy receptor that inhibits osteoclast activity.
Localization (secreted) of osteoprotegerin in osteoclast associated with cancer pain and bone cancer
3) Confidence 0.71 Published 2000 Journal Pain Med Section Abstract Doc Link 15101876 Disease Relevance 1.22 Pain Relevance 1.00
Different from BM-MSCs, dermal fibroblasts were found to release high levels of IL6 and osteoprotegerin in this study.
Localization (levels) of osteoprotegerin in fibroblasts
4) Confidence 0.17 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2270908 Disease Relevance 0.74 Pain Relevance 0.34
Different from BM-MSCs, dermal fibroblasts were found to release high levels of IL6 and osteoprotegerin in this study.
Localization (release) of osteoprotegerin in fibroblasts
5) Confidence 0.17 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2270908 Disease Relevance 0.74 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox